Marshall University

Marshall Digital Scholar
Theses, Dissertations and Capstones

2018

Is Preoperative Administration of Celecoxib and
Pregabalin Associated with Decreased
Intraoperative and Postoperative Opioid
Consumption in Patients Undergoing Total Hip or
Knee Arthroplasty?
Cierra Treadway
cierratreadway@yahoo.com

Follow this and additional works at: https://mds.marshall.edu/etd
Part of the Anesthesiology Commons
Recommended Citation
Treadway, Cierra, "Is Preoperative Administration of Celecoxib and Pregabalin Associated with Decreased Intraoperative and
Postoperative Opioid Consumption in Patients Undergoing Total Hip or Knee Arthroplasty?" (2018). Theses, Dissertations and
Capstones. 1117.
https://mds.marshall.edu/etd/1117

This Research Paper is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for inclusion in Theses, Dissertations
and Capstones by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu,
beachgr@marshall.edu.

IS PREOPERATIVE ADMINISTRATION OF CELECOXIB AND PREGABALIN
ASSOCIATED WITH DECREASED INTRAOPERATIVE AND POSTOPERATIVE OPIOID
CONSUMPTION IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY?

A Research Project submitted to
the Marshall University
Graduate School of Management

Final defense submitted in partial fulfillment
of the requirements for the
Doctorate of Management Practice in Nurse Anesthesia (DMPNA) degree
Conferred by Marshall University in Partnership with the
Charleston Area Medical Center (CAMC) Based on a Collaborative Agreement between
The MU Graduate School of Management and the CAMC School of Nurse Anesthesia

By:
Cierra Treadway RN, BSN

Marshall University
September 4, 2018

i

SIGNATURE PAGE
Approved by:

__________________________________________________

_______________

Dr. Mike Frame, DMPNA, APRN, CRNA

Date

Committee Chair
CAMC School of Nurse Anesthesia

__________________________________________________

_______________

Dr. Alberto Coustasse-Hencke, Dr.PH., MD, MBA, MPH

Date

Graduate College of Business, Marshall University

__________________________________________________
Dr. Nichole Stowers, DMPNA, APRN, CRNA

_______________
Date

CAMC Health System, Memorial Hospital

ii

TABLE OF CONTENTS
COVER PAGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Page
i

SIGNATURE PAGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ii

TABLE OF CONTENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

iii

EXECUTIVE SUMMARY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

iv

LIST OF TABLES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

vi

INTRODUCTION
•

Background and Significance of the Problem . . . . . . . . . . . . . . . . . . . . . . . .

1

•

Literature Review. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

•

Statement of the Problem and Research Purpose. . . . . . . . . . . . . . . . . . . . . .

7

METHODOLOGY
•

Research Hypotheses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8

•

Research Design/Setting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8

•

Sample Population with Description of Sample. . . . . . . . . . . . . . . . . . . . . . .

9

•

Procedures and Protocol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10

•

Data Collection and Instrumentation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

11

•

Statistical Design and Analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12

•

Ethical Considerations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12

RESULTS
•

Presentation, Analysis and Interpretation of Data . . . . . . . . . . . . . . . . . . . .

12

DISCUSSION
•

Discussion of Study Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

18

•

Study Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

20

IMPLICATIONS AND RECOMMENDATIONS . . . . . . . . . . . . . . . . . . . . . . . . . .

21

CONCLUSION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . .

21

REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

22

APPENDICES
•
•
•
•

Appendix A: Data Collection Tool 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Appendix B: Data Collection Tool 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Appendix C: ICD-10-PCS THA and TKA Codes. . . . . . . . . . . . . . . . . . . . .
Appendix D: IRB Approval Letter. . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .

27
27
28
38

iii

EXECTUTIVE SUMMARY
Abstract: The purpose of this study was to determine if a preoperative dose of celecoxib and
pregabalin in patients who underwent total hip arthroplasty (THA) or total knee arthroplasty
(TKA) was associated with less opioid consumption intraoperatively and postoperatively
compared to those who did not receive this regimen.
Introduction: THA and TKA have been associated with a high incidence of postoperative pain.
Historically, this pain has been managed with opioids; however, these drugs have negative side
effects associated with their use. Consequently, anesthesia providers have begun utilizing
multimodal non-opioid analgesics. Recently, a specific combination has been utilized, which
includes a nonsteroidal anti-inflammatory drug known as celecoxib (Celebrex) and an
anticonvulsant known as pregabalin (Lyrica). While this combination may be a beneficial
alternative for opioids, there is no consensus on the timeliness or effectiveness of a single
combination dose of these drugs at alleviating perioperative pain.
Methodology: A retrospective cross-sectional study design was utilized for this study that
included 200 patients who underwent THA or TKA between May 1, 2008 and May 1, 2018 at
Charleston Area Medical Center. A total of 100 patients were included in group one, which
consisted of patients who did not receive a preoperative dose of celecoxib and pregabalin or any
other preoperative analgesics. Group two consisted of 100 patients who did receive a
preoperative dose of both celecoxib and pregabalin. The primary independent variable was the
preoperative administration of celecoxib and pregabalin. Secondary independent variables
consisted of gender, age, body mass index (BMI), and American Society of Anesthesiologists
(ASA) physical classification scores. The dependent variables consisted of intraoperative opioid
consumption and total opioid consumption in the postoperative anesthesia care unit (PACU).
Control variables consisted of gender, age, BMI and ASA physical classification scores. The
research hypotheses were that patient who underwent THA or TKA and received preoperative
doses of both celecoxib and pregabalin would have less opioid consumption in the intraoperative
period and less opioid consumption in the PACU, compared to those who did not receive the
same combination preoperatively.
Results: Comparison of the two groups yielded no differences between mean age, BMI or
gender. The mean age and ASA classification between the two groups were statistically
different, p=.0001 and p=.017. Group one consisted of 55 females and 45 males, while group
two consisted of 52 females and 48 males. The study also revealed there was a statistical
significance in terms of PACU opioid consumption (p=.001) between the two groups but no
statistical difference in intraoperative opioid consumption (p>.05). Group one received a mean
difference of approximately 1.2 morphine equivalents more than group two. There was no
statistical significance between PACU opioid consumption and age, gender, BMI, or ASA
classification. Analysis showed there was a statistical association between intraoperative opioid
consumption and age (p=.022) and gender (p=.025). Further analysis revealed females received a
mean of 3.22 morphine equivalents more than males.
Discussion: The study results supported the hypothesis that preoperative celecoxib and
pregabalin would be associated with a decrease in PACU opioid consumption in patients
undergoing THA or TKA. These results did not support the additional study hypothesis that this
combination would also decrease intraoperative opioid consumption.
Implications and Recommendations: The results of this study supported the use of
preoperative celecoxib and pregabalin at reducing PACU opioid consumption. Additional
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prospective, randomized studies are needed to compare the use of celecoxib and pregabalin
independently versus in combination.
Conclusion: In conclusion, this study found an association between the preoperative
administration of celecoxib and pregabalin in patients undergoing THA or TKA and decreased
PACU opioid consumption; however, no association was found between the preoperative
administration of celecoxib and pregabalin and decreased intraoperative opioid consumption in
these patients.
Key Words: Arthroplasty, celecoxib, opioid, pregabalin, pain
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INTRODUCTION
Background and Significance of the Problem
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are surgical procedures
in which damaged cartilage and bone are removed from the hip or knee area and replaced with
prosthetic components (American Academy of Orthopaedic Surgeons, 2015a, 2015b). According
to a 2010 report from the National Center for Health Statistics, TKA is the most commonly
performed inpatient surgery on patients aged 45 years and older with an approximate 693,400
being performed annually (Williams, Woldford, & Bercovitz, 2015). This number has been
predicted to increase to 3.48 million per year by 2030 (Kurtz, Ong, Lau, Mowat, & Halpern,
2007). In comparison, THA surgeries have been predicted to increase from 326,100 annually to
526,000 by 2030 (Kurtz et al., 2007; Woldford, Palso, & Bercovitz, 2015).

The primary indication for THA or TKA is a chronic pain disease known as
osteoarthritis, which affects more than 30 million adults in the United States (Centers for Disease
Control and Prevention [CDC], 2017; National Institutes of Health, 1994). Osteoarthritis is a
chronic pain disease that causes cartilage to breakdown in bones and joints that leads to stiffness
and edema (CDC, 2017). While people suffering from osteoarthritis undergo total joint
arthroplasty to relieve these symptoms, this type of surgery often leads to chronic postoperative
pain (Peterson & Arendt-Nielson, 2016). This chronic pain can lead to prolonged recovery,
increased morbidity, chronic opioid use, and increased health care costs (Gan, 2017). Therefore,
managing pain during this period for patients undergoing THA or TKA has remained a challenge
for anesthesia providers. In the past, opioids have been the mainstay of pain management in
these procedures; however, opioids have adverse effects associated with their use such as
constipation, nausea and vomiting, respiratory depression, tolerance, and physical dependence
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(Benayamin et al., 2008; Golladay, Balch, Dalury, Satpathy, & Jiranek, 2017). To decrease the
negative side effects associated with opioids, surgeons and anesthesia providers have begun
utilizing multimodal analgesic techniques that include both opioid and non-opioid analgesics
(Halawi, Grant, & Bolognesi, 2015). These non-opioid analgesics have included local
anesthetics, anticonvulsants such as pregabalin and gabapentin, and nonsteroidal antiinflammatory drugs (NSAID) such as acetaminophen, ketorolac and celecoxib (Halawi et al.,
2015). While some studies have shown that multimodal analgesic techniques can be effective in
managing postoperative pain, other studies have indicated that these techniques have
demonstrated no superiority to opioids and may actually increase opioid consumption, healthcare
costs, and postoperative delirium (Brooks, Freter, Bowles, & Amirault, 2017; Halawi et al.,
2015).

Many non-opioid analgesics have not been formulated for intravenous use; therefore,
they are administered orally and preoperatively and are considered preemptive analgesics.
Preemptive analgesics are pain relieving treatments that are administered before surgical incision
that continue to exert their effects throughout the procedure to the initial postoperative period
(Kissin, 2000). Preemptive analgesics inhibit central sensitization, which is an altered response
to pain that intensifies postoperative pain (Kissin, 2000). Preventing central sensitization can
decrease chronic pain, which has been reported to be 12.4% of patients who undergo THA or
TKA. (Golladay et al., 2017; Nikolajsen, Brandsborg, Lucht, Jensen, & Kehlet, 2006).

A specific preemptive non-opioid combination that has been utilized during THA and
TKA surgeries is celecoxib and pregabalin (Carmichael et al., 2013). Although specific studies
have not been conducted to demonstrate if synergistic effects exist between pregabalin and
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celecoxib, studies have indicated that when pregabalin is combined with other NSAIDs, such as
naproxen, a synergistic relationship exists (Hurley, Chatterjea, Rose Feng, Taylor, & Hammond,
2002). Analgesic drugs are believed to be synergistic if they exhibit a greater pain-relieving
effect when used in combination than when either drug is used alone.

Literature Review

NSAIDs such as celecoxib have been used around the world to treat pain and
inflammation for over 100 years (Vane, 2000). NSAIDs demonstrate their effects by inhibiting
the prostaglandin producing catalytic enzyme prostaglandin H2 synthase (PGHS), also known as
cyclooxygenase (COX) (Vane, 1971). There are two types of cyclooxygenase enzymes:
cyclooxygenase type 1 (COX-1) and cyclooxygenase type 2 (COX-2) (Seibert et al., 1994).
COX-1 enzymes participate in physiological hemostasis and maintain the integrity of the
gastrointestinal and renal system, while COX-2 enzymes are inducible enzymes that are only
present at sites of inflammation (Vane, Bakhle, & Botting, 1998).

Pharmacologic agents that interfere with these enzymes have been known to decrease
pain and inflammation and are referred to as cyclooxygenase inhibitors (Vane et al., 1998).
These drugs work by selectively inhibiting either COX-1 or COX-2, or simultaneously inhibiting
both enzymes (Vane et al., 1998). The nonselective forms of these drugs, such as aspirin,
naproxen, and ibuprofen have been used to treat pain associated with the inflammation process,
but these drugs exhibit other side effects such as decreased platelet functioning and increased
gastrointestinal toxicity (Vane et al., 1998).
While nonselective COX inhibiting drugs have proven to be beneficial for specific types
of patients, such as those suffering with thrombotic disorders, their use in the perioperative area
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can lead unwanted side effects such as increased blood loss during surgery (Connelly & Panush,
1991). These unwanted side effects have limited the use of nonselective NSAIDs in the
perioperative period. Consequently, most NSAIDs are stopped days or even weeks before
surgery; however, because a selective cyclooxygenase inhibitor such as celecoxib only
demonstrates its effects on COX-2 enzymes it does not interfere with normal platelet function
(Teerawattananon, Tantayakom, Suwanawiboon, & Katchamart, 2017). Therefore, it does not
increase the risk of intraoperative bleeding (Teerawattananon et al., 2017). These beneficial
pharmacologic properties have led to an increased use of celecoxib in the perioperative period;
however, celecoxib must be administered orally three hours before surgical incision in order to
be effective in treating pain (Pfizer INC, 2015).
Currently, celecoxib is the only Food and Drug Administration (FDA) approved selective
NSAID available in the United States. Previous COX-2 selective inhibitors such as valdecoxib
and rofecoxib have been removed from the market due to an increased risk of adverse
cardiovascular effects with their use (U.S Food & Drug Administration, 2018). In order to
remain on the market the FDA ordered the manufacturer to complete a cardiovascular safety
trial, which is now known as the Prospective Safety Versus Ibuprofen or Naproxen
(PRECISION) trial (Nissen et al., 2016). The authors concluded that celecoxib had less risk of
gastrointestinal side effects than naproxen and less renal side effects than ibuprofen. The authors
also suggested that moderate doses of celecoxib were not associated with an increased risk of
cardiovascular events when compared to nonselective NSAIDs such as naproxen and ibuprofen.
Due to the findings of this study, as of today, celecoxib remains on the market in the United
States for the treatment of pain.
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The FDA approved pregabalin 2004 for the treatment of peripheral neuropathy,
neuralgia, and seizures. Since then, it has also been approved for the treatment of a chronic pain
illness known as fibromyalgia and neuropathic pain (Pfizer Pharmaceuticals LLC, 2011). While
pregabalin is a structural analog of the inhibitory neurotransmitter known gamma-aminobutyric
acid (GABA), it does not exert its action at GABA receptor sites (Pfizer Pharmaceuticals LLC,
2011). Instead, the drug binds to voltage-gated calcium channel receptors in the central nervous
system and decreases the release of neurotransmitters that signal pain (Pfizer Pharmaceuticals
LLC, 2011). Although this mechanism of action is not fully understood, it is believed that
pregabalin interferes with the pain transmission pathway from the brainstem to the spinal cord
that is involved in the formation of chronic pain (Pfizer Pharmaceuticals LLC, 2011).
Various studies have been performed to determine the effectiveness of celecoxib and/or
pregabalin during total joint arthroplasty, but most focus on the long-term effectiveness of both
preoperative and repeated postoperative doses of these drugs. In 2015, a prospective randomized
control trial that consisted of a total of 64 participants who underwent THA showed that patients
who received a preoperative 400 milligram (mg) dose of celecoxib and additional scheduled 200
mg doses of celecoxib every 12 hours had decreased pain scores at 12, 24, 48, and 72 hours after
surgery (Chen et al., 2015). Additionally, the treatment group had decreased opioid consumption
at 6, 12, and 24 hours postoperatively compared to the control group. While the treatment group
consisted of both preoperative and postoperative doses of celecoxib, decreased opioid
consumption at 6 hours in the treatment group suggested that a single preoperative dose of
celecoxib may have been effective in alleviating pain in the immediate postoperative period
because repeated doses were not administered until 12 hours after surgery. Additionally, the
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incidence of postoperative nausea and vomiting was lower in the treatment group (Chen et al.,
2015).
In 2012, a randomized double-blind placebo study that consisted of ninety patients
undergoing distal extremity surgery compared the effectiveness of a single preoperative dose of
200 mg of celecoxib versus 320 mg of acetaminophen (Kashefi, Honarmand, & Safavi, 2012).
The authors of this study showed that pain scores four hours postoperatively were significantly
lower in the celecoxib group compared to the acetaminophen and placebo group. Additionally,
this study found that there were no statistically significant differences in pain scores in the three
groups four hours after surgery.
In 2015, a prospective, randomized controlled trial that included 120 participants
evaluated postoperative pain in patients undergoing TKA (YaDeau et al., 2015). Authors
discovered that patients who had received preoperative and postoperative doses of pregabalin in
addition to an NSAID did not have decreased pain or opioid consumption compared to those
who received the same regimen without pregabalin. The authors also revealed that patients in the
pregabalin group had increased sedation on postoperative day one.
In 2011, a randomized placebo-controlled trial that consisted of 50 participants
undergoing discectomy showed that the treatment group who received a single 150 mg dose of
pregabalin had reduced preoperative anxiety and postoperative pain (Spreng, Dahl, & Raeder,
2011). Although pain scores and morphine consumption did not differ significantly 24 hours
postoperatively between the two groups, the authors did reveal that patients in the pregabalin
group were able to be discharged from the post anesthesia care unit (PACU) earlier and had
significantly lower pains scores at 120 minutes postoperatively. A similar double-blind
randomized controlled trial in 2011, that consisted of 32 patients, demonstrated that a single 300
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mg dose of pregabalin did not reduce pain intensity in patients undergoing discectomy; however,
compared to the placebo, the pregabalin group did have decreased morphine consumption.
(Hegarty & Shorten, 2011).
A 2015, a double-blind, randomized, placebo-controlled study that consisted of 184
participants showed that patients undergoing THA, who received a preoperative and
postoperative combination of celecoxib and pregabalin, had less morphine consumption 12, 24,
and 48 hours postoperative compared to the placebo group who received the same anesthetic
regimen without pregabalin (Clarke et al., 2015). The authors also discovered that pain scores
were lower 1-7 days after discharge. Another randomized controlled trial conducted in 2012 that
consisted of 60 participants compared the analgesic effectiveness of preoperative celecoxib
versus pregabalin during open cholecystectomy procedures (Ali & Babar, 2012). The authors
concluded that neither drug was superior because there were no significant differences in
postoperative pain scores, opioid consumption, or incidence postoperative nausea and vomiting
between the two treatment groups (Ali & Babar, 2012). It was also noted in the study that the
pregabalin group had a higher frequency of sedation.

Statement of the Problem and Research Purpose

Due to the predicted increase in total joint arthroplasties previously mentioned, the
increasing age of the patient population undergoing THA and TKA, and the deleterious side
effects of opioids, it is essential for surgeons and anesthesia providers to continue investigating
the efficacy of multimodal pain management. While the use of preemptive multimodal
combinations such as pregabalin and celecoxib in THA and TKA has been explored, there is no
consensus on the effectiveness of single combination doses or the timeliness of this specific drug
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combination at alleviating pain in the immediate postoperative period, therefore; further studies
are warranted. The purpose of this study was to determine if a preoperative dose of celecoxib and
pregabalin in patients who underwent THA or TKA was associated with less opioid consumption
intraoperatively and postoperatively compared to those who did not receive this regimen. The
importance of this study was to evaluate if orally administered non-opioid analgesics
combinations such as these are an effective tool for anesthesia providers to utilize in the
perioperative period. The findings of this study could lead to improved evidence based clinical
practices and enhanced patient outcomes at Charleston Area Medical Center (CAMC) in
Charleston, West Virginia and other facilities that perform THA or TKA.

METHODOLOGY
Research Hypotheses
The specific aim of this study was to evaluate the effectiveness of preemptive non-opioid
analgesics in THA and TKA. The main objective of this study was to evaluate the effectiveness
of preoperative celecoxib and pregabalin administration at reducing intraoperative and
postoperative opioid consumption. There were two proposed hypotheses for this study. The
hypotheses were:
1. Patients who underwent THA or TKA and received preoperative doses of both celecoxib
and pregabalin will have less opioid consumption in the intraoperative period compared
to those who did not receive the same combination preoperatively.
2. Patients who underwent THA or TKA and received preoperative doses of both celecoxib
and pregabalin will have less opioid consumption in the PACU compared to those who
did not receive the same combination preoperatively.
Research Design/Setting
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The study design chosen was a retrospective cross-sectional design. This type of study
design allowed for rapid cost efficient data collection for the intended patient population
(Jacobsen, 2017). Data was collected from medical records at CAMC in Charleston, WV.
CAMC is a non-profit hospital that is made up of 965 beds (Charleston Area Medical Center
[CAMC], 2018). CAMC is made up of four divisions: CAMC General Hospital, CAMC
Memorial Hospital, CAMC Women and Children’s Hospital and CAMC Teays Valley Hospital
(CAMC, 2018).
Sample Population and Description of Sample
A retrospective chart review was performed on patients who underwent elective THA or
TKA between May 1, 2008 and May 1, 2018 at CAMC. The sample population was divided into
two groups for comparison. Group one consisted of 100 patients who underwent THA or TKA
that did not receive both celecoxib and pregabalin preoperatively or any other preoperative
analgesics. Group two consisted of 100 patients who underwent THA or TKA that did receive
pregabalin and celecoxib.
The sample was identified using codes for THA and TKA surgeries from both the
International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) and
International Classification of Diseases 10th revision Procedure Coding System (ICD-10-PCS).
The ICD-9-CM code for THA is 81.52. The ICD-9-CM code for TKA is 81.54. ICD-10 PCS
codes for THA and TKA are listed in Appendix C.
Inclusion criteria:
1. Adult male or female 18 years of age or older
2. Patients who had an American Society of Anesthesiologist (ASA) physical
classification I-IV
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3. Patients who underwent THA or TKA
4. Patients who received both celecoxib and pregabalin preoperatively
Exclusion criteria:
1. Patients less than 18 years old
2. Patients with allergies to celecoxib or pregabalin
3. Patients who underwent emergent or traumatic THA or TKA
4. Patients who received opioids preoperatively
5. Patients who received spinal anesthesia
6. Patients who received pregabalin or celecoxib in a single dose preoperative and not in
combination
7. Patient who received any other analgesics preoperatively
8. Patients who had an American Society of Anesthesiologist (ASA) physical
classification V or VI
Procedures/Protocol
A retrospective chart review was performed on patients who underwent elective THA or
TKA between May 1, 2008 and May 1, 2018 at CAMC. A sample size of 200 patients was
utilized. Patient demographics and clinical information were collected and included: age, gender,
body mass index (BMI), ASA classification, the preoperative administration of both celecoxib
and pregabalin or lack of, intraoperative opioid consumption, and total opioid consumption while
in the PACU. These variables were collected from the Electronic Medical Record (EMR),
Medication Administration Record (MAR), PACU record and intraoperative anesthesia record.
The primary independent variable was the preoperative administration of a combination of
celecoxib and pregabalin. Secondary independent variables consisted of gender, age, BMI, and
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ASA physical class scores. The dependent variables were total intraoperative and opioid
consumption while in the PACU.
Patient age was calculated on day of surgery. Patient gender was defined as male or
female. BMI was determined by extracting patients’ height in centimeters (cm) and weight in
kilograms (kg). BMI was calculated by dividing the patients weight in kg by their height squared
in meters (CDC, 2018). ASA physical classification scores were collected, which is a grading
tool used by anesthesia providers to classify a patient’s health status. Class I includes healthy
patients with no comorbities, Class II includes patients with mild systemic disease, Class III
includes patients with severe noncapactitiating systemic disease, Class IV includes patients with
incapacitiating systemic disease that threatens life, Class V is reserved for patients that are not
expected to live without surgery, and Class VI consists of organ donating patients have been
declared brain dead (American Society of Anesthesiologists, 2014). Opioid consumption was
recorded from the EMR and anesthesia record and converted to morphine equivalents to permit a
standard comparison among various opioids.
Data Collection and Instrumentation
Data was extracted from each patient’s EMR and organized using a Microsoft Excel
spreadsheet. The EMR for each patient was accessed and data was extracted from the MAR,
preoperative evaluation, intraoperative anesthesia record, and PACU record. An anonymous
number was assigned to each patient in Data Collection Tool 1 (Appendix A) to maintain
confidentiality. Data Collection Tool 2 (Appendix B) was utilized to organize data that was
collected and included age, gender, ASA classification, weight, BMI, celecoxib and pregabalin
administration or the lack thereof, total intraoperative opioid consumption and total opioid
consumption in the PACU.
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Statistical Design and Analysis
The main purpose of this study was to determine if there was an association between a
preoperative dose of celecoxib and pregabalin and decreased perioperative opioid consumption
in patients who underwent THA or TKA. The primary independent variable was the preoperative
administration of celecoxib and pregabalin. Secondary independent variables consisted of
gender, age, BMI, and ASA physical class scores. The dependent variables consisted of
intraoperative and PACU opioid consumption. Independent t-tests were performed to compare if
statistical differences existed between age and BMI in the two groups. A chi-squared test was
performed to determine if a statistical difference existed between gender and ASA between the
two groups. Two step-wise linear regression was used to predict a statistical association between
celecoxib and pregabalin administration, age, BMI, gender, ASA classification with
intraoperative opioid consumption and opioid consumption in PACU. IBM SPSS statistical
software was utilized to analyze data. A p-value of <.05 was considered statistically significant.
Ethical Considerations
This study was approved by the CAMC/West Virginia University Internal Review Board
on June 12, 2018 (Appendix D).
RESULTS
Presentation, Analysis, and Interpretation of the Data

The study sample consisted of 200 patients aged 40-90 years of age who underwent THA
or TKA at CAMC. The sample was divided into two groups. Group one consisted of 100
patients who underwent THA or TKA and did not receive celecoxib and pregabalin
preoperatively or any other preoperative analgesics. Group two consisted of 100 patients who
underwent THA or TKA and received a preoperative combination of celecoxib and pregabalin.
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Independent t-tests were used to compare differences in mean age and BMI between the
two groups. Mean BMI between the two group was not significantly different (p=>.05). The
mean age difference between the two groups was statistically different p=.0001. The mean age
for group one was 66.50 ± 9.8 years and the mean age for group two was 59.27 ± 8.6 years.
Mean BMI for group one was 33.59 ± 7.09 (kg/m2) and for group two was 32.68 ± 5.9 (kg/m2).
Chi-squared test was performed to compare gender and recoded ASA classification between the
two groups. Gender between the two groups was not statistically different, (p>.05). Group one
consisted of 55 females and 45 males, while group two consisted of 52 females and 48 males A
significant difference existed between the two groups in terms of ASA classification p=.017
(p<.05). Group one had 20 ASA class 1-2 patients and 80 ASA class 3-4 patients. Group two had
35 ASA class 1-2 patients and 65 ASA class 3-4 patients. Each group consisted of 57 patients
who underwent TKA and 43 patients who underwent THA, (Table 1).

Table 1: Demographics and Clinical Characteristics of Patients Who Underwent Total Hip or Knee
Arthroplasty and Comparisons of Age, BMI, Gender, and ASA Class

Total Sample

Variable

Age (years)
BMI (kg/m2)
Gender (F/M) (N)
Female

Total
N=100
Mean (SD)
32.7 (9.2)
33.12 (3.0)

Study Groups
Did not receive
celecoxib and
pregabalin
N=100 (50%)
Mean (SD)
66.50 (9.8)
33.59 (7.09)

Received
celecoxib and
pregabalin
N=100 (50%)
Mean (SD)
59.27 (8.6)
32.68 (5.90)

F = 107

F = 55

F = 52

M = 93

M =45

M = 48

Statistical
Value

p-Value

.0001*
(NS)

(NS)
Male
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ASA 1-2 N (%)

55 (27.5%)

20 (20%)

35 (35%)

ASA 3-4 N (%)

145 (72.5%)

80 (80%)

65 (65%)

.018*

THA
TKA

114 (57%)

57 (57%)

86 (43%)

43 (43%)

57 (57%)
NS
43 (43%)

*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation,
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status
classification, F=female, M=male.
There was no statistical significance between the two groups when comparing mean
intraoperative opioid consumption, (p>.05). Mean intraoperative opioid consumption was 22.56
± 10.6 morphine equivalents for group 1 and 22.81 ± 9.8 morphine equivalents for group 2. A
comparison of the two groups showed statistical significance between the two groups in mean
PACU opioid consumption, p=.001. Group one received a mean of 3.59 ± 3.65 morphine
equivalents and group two received a mean of 2.15 ± 2.56 morphine equivalents, (Table 2).

Table 2: Comparison of Intraoperative and PACU Opioid Consumption Between Group One and
Group Two
Total Sample
Study Groups
Statistical Value

Variable

Intraoperative
opioid
administration
(morphine
equivalents)
PACU opioid
administration
(morphine
equivalents)

Total Sample
N=100
Mean (SD)

Did not receive
celecoxib and
pregabalin
N=100 (50%)
Mean (SD)

Received
celecoxib and
pregabalin
N=100 (50%)
Mean (SD)

23.2 (10.2)

22.8 (9.8)

23.6 (10.6)

(NS)

2.9 (2.6)

3.6 (3.7)

2.2 (2.6)

.001*

p-Value
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* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation,
PACU = post-anesthesia care unit.
Linear regression was used to identify statistical association between mean intraoperative
opioid consumption and the following independent variables: age, gender, BMI, recoded ASA
class, and the preoperative administration of celecoxib and pregabalin or lack thereof. There was
no statistical significance between mean intraoperative opioid consumption and BMI, ASA, or
celecoxib/pregabalin administration or the lack thereof (p>.05). There was a statistical
significance between intraoperative opioid consumption when considering age (p=.022) and
gender (p=.025), (Table 3).

Table 3: Linear Regression Analysis Between Age, BMI, ASA, Celecoxib and Pregabalin Use,
and Intraoperative Opioid Consumption in Patients Undergoing Total Hip or Knee Arthroplasty

Model
1
(Constant)
Age*
Gender:*
BMI
ASA
Celecoxib and
Pregabalin

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
31.723
7.394
-.184
.080
-.179
3.199
1.414
.157

t
4.291
-2.302
2.263

Sig.
.0001
.022*
.025*

.114

.113

.073

1.004

.317

-2.403

1.617

-.106

-1.486

.139

-9.32

1.529

-0.46

-.610

.543

*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation,
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status
classification, F=female, M=male, Y=yes N=no.
Linear regression was used to identify statistical association between PACU opioid
consumption and the following independent variables: age, gender, BMI, recoded ASA class,
and the preoperative administration of celecoxib and pregabalin or lack thereof. There was no
statistical association between PACU opioid consumption and age, gender, ASA, and BMI.
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There was a statistical significance between PACU opioid consumption and the administration of
celecoxib or pregabalin or the lack thereof p=.002, (Table 4).

Table 4: Linear Regression Analysis Between Age, BMI, ASA, Celecoxib and Pregabalin Use,
and PACU Opioid Consumption in Patients Undergoing Total Hip or Knee Arthroplasty
Unstandardized
Coefficients
Model
1

(Constant)
Age
Gender:
BMI
ASA
Celebrex and
Pregabalin

Standardized
Coefficients

B
3.325
-.020

Std. Error
2.355
.025

.713
.023
.622
-1.499

t

Beta

Sig.

-.061

1.412
-.780

.160
.437

.450
.036
.515

.110
.046
.086

1.583
.637
1.207

.115
.525
.229

.487

-.232

-3.079

.002*

*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation,
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status
classification, F=female, M=male, Y=yes N=no.
An independent t-test was used to compare gender with intraoperative and PACU
opioids. There was no statistical association between total PACU opioids and gender. There was
a statistical significance between total intraoperative opioids and gender (p=.21), (Table 5).

Table 5: Independent t-test Comparing Gender and Intraoperative and PACU Opioid
Consumption

Total Intraoperative
Opioids*
Total PACU Opioids

Equal variances assumed
Equal variances not
assumed
Equal variances assumed
Equal variances not
assumed

t-test for Equality of Means
Mean
df
Sig. (2-tailed) Difference
198
.21*
3.3102
194.592

.19

3.3102

198

.588

.2494

189.183

.578

.2494

16

* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation,
PACU = post-anesthesia care unit
An independent t-test was conducted to assess if there was a statistical significance
between males or females. In terms of intraoperative opioids, females received a mean 21.68 ±
10.14 morphine equivalents and males received a mean 24.92 ± 9.98 morphine equivalents.
These finding were statistically significant p<.05, (Table 6).

Table 6: Independent T-Test Comparing Gender and Intraoperative Opioid Consumption in
Patients Undergoing TKA or THA

Intraoperative Opioids
(morphine equivalents)

Gender: M=1, F = 0
F

N

Mean

Std. Deviation

107

21.68

10.1359

M

93

24.920

9.9768

* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation,
F=female, M=Male.
Independent t-tests were conducted to determine if there was a statistical significance
between type of surgery (THA or TKA) and age. Mean age for patients undergoing TKA in the
study was 63.96 ± 8.208 and for THA was 61.45 ± 11. 621.There was no statistical significance
between type of surgery and age (p>.05), (Table 7).

Table 7: Independent T-Test Comparing Type of Surgery (TKA or THA) and Age

Age (years)

Surgery: TKA/THA
TKA
THA

N
114
86

Mean
63.96
61.45

Std. Deviation
8.208
11.621

Sig. (2-tailed)
.075
.075

Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation,
TKA=total knee arthroplasty, THA=total hip arthroplasty.
Further analysis was performed to determine if there was a statistical association between
type of surgery and gender. There were 65 females and 49 males in the TKA group. There was
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42 females and 44 males in the THA group. There was no statistical association between gender
and type of surgery (p>.05), (Table 8).

Table 8: Chi-Square Test Comparing Type of Surgery (TKA or THA) and Gender
Gender: F or M
F
M

TKA
65

THA
42

49

44

Total

Sig. (2-tailed)
.251
107
93

.251

Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation,
TKA=total knee arthroplasty, THA=total hip arthroplasty.
DISCUSSION
Discussion of Study Results

The purpose of this study was to determine if an association could be made between a
preoperative dose of celecoxib and pregabalin in patients undergoing THA or TKA and their
intraoperative and PACU opioid consumption. The hypotheses predicted that patients who
received a preoperative dose of both celecoxib and pregabalin would consume less opioids
intraoperatively and postoperatively. The study revealed there was a statistical significance in
terms of PACU opioid consumption between the two groups but no statistical difference in
intraoperative opioid consumption. The group that did not receive celecoxib and pregabalin
preoperatively (group one) received a mean difference of approximately 1.2 morphine
equivalents more than group two.

Independent t-tests and chi-squared tests revealed that mean BMI and gender between the
two groups was not statistically significantly different; however, ASA classification and age
were statistically significantly different between the two groups. Group one, that did not receive
celecoxib and pregabalin, had more patients with ASA 3-4 classifications and were older by a

18

mean of approximately 7 years. Therefore, based on previous research on this topic, it would be
anticipated that group one would have required less opioids due to the mean age of this group
being greater (Kanonidou & Karystianou, 2007). However, the results of this study showed that
there was an increased amount of opioid consumption in group one which had older aged
patients. This could be also be attributed to the increased number of ASA 3-4 class patients in
this group. Further research is needed to determine if there are associations between higher ASA
classifications and opioid consumption.

Independent t-tests showed that there was a statistical significance between intraoperative
opioid consumption and age and gender. Further, independent t-tests revealed that females
received less opioids intraoperatively, approximately 21.68 morphine equivalents compared to
males receiving 24.9 morphine equivalents. This study is consistent with findings from a 2003
study in which the authors revealed that females are more sensitive than males to the effects of
opioids; therefore, they require a lesser amount (Pleym, Spigset, Kharasch, & Dale, 2003).

Further analysis was conducted to examine the association between age and both
intraoperative and PACU opioid consumption. Patients were assigned to two groups. Group A
consisted of patients aged 40-64 years and group B consisted of patients aged 65-90 years. The
analysis showed there was no statistical difference between the groups in terms of PACU opioid
consumption. The analysis showed that the older aged group (group B) received approximately
3.3 morphine equivalents less than group A. The older aged group (group B) received a mean of
21.42 ± 11.22 morphine equivalents and the younger aged group (group A) received 24.725 ±
11.22 morphine equivalents. These results are in consensus with the previous research mentioned
that found a decreased opioid need in older aged patients (Kanonidou & Karystianou, 2007).

19

A 2015 study revealed that patients who underwent THA were approximately 65 years
old and those who underwent TKA were approximately 67 years old (Fang, Noiseux, Linson, &
Cram, 2015). Additional analysis was conducted to determine if there was a statistical
association between the type of surgery (TKA or THA) and age in the current study. The mean
age for patients undergoing TKA in this study was 63.96 ± 8.208 and for THA was 61.45 ± 11.
621. While the results of the current study do not concur with the results of the previously
mentioned study, there was no statistical significance between the two groups in terms of age and
types of surgery (p>.05). There was also no significant association between type of surgery
(THA or TKA) and gender, (p>0.05).

Study Limitations

There were numerous limitations to this research. Most influentially was the retrospective
nature of the study which did not allow for total control of the variables. Retrospective crosssectional studies have less control of variables than prospective studies; consequently, this type
of study could not prove causation only association.

Numerous cofounding variables could have affected the results such as the administration
of NSAIDs as well as the use of local anesthetics. The author was unable to control these
variables or convert the doses of those medications into morphine equivalents. Another variable
that may have affected the results is the type of surgery since both THA and TKA were included
to allow for a larger sample size. Differences in personnel such as surgeons, anesthesia
providers, and nursing staff may have influenced the total opioid consumption. Additionally,
variations in charting between anesthesia providers and nursing staff could have affected the
study. Additional prospective studies are needed in the future to compare the use of celecoxib
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and pregabalin when administrated separately compared to when used in combination dose in
total joint replacement surgery.

IMPLICATIONS AND RECOMMENDATIONS

The results of this study supported the use of preoperative celecoxib and pregabalin at
reducing PACU opioid consumption. In the future, additional prospective, randomized studies
are needed to compare the use of celecoxib and pregabalin independently versus in combination.
In these studies, variables such as specific type of joint replacement surgery and perioperative
administration of an NSAID and any local anesthetic use must be controlled.

CONCLUSION

In conclusion, this study found an association between the preoperative administration of
celecoxib and pregabalin in patients undergoing THA or TKA and decreased PACU opioid
consumption; however, no association was found between the preoperative administration of
celecoxib and pregabalin and decreased intraoperative opioid consumption. The results of this
study can improve patient outcomes in patients undergoing TKA or THA at CAMC or similar
facilities where these procedures are performed.
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APPENDICES
Appendix A: Data Collection Tool 1
Patient Safety Number

Patient Identification Number

1
2
3
4
5
…
200
Appendix B: Data Collection Tool 2
Study

Age

Gender

ASA

Weight

BMI

Celecoxib

Total

Total PACU

#

(years)

(Male=1

(I-IV)

(kg)

(kg/m2)

and

Intraoperative

Opioids (morphine

Pregabalin

Opioids

equivalents)

(Y=1, N=0)

(morphine

Female=0)

equivalents)

1
2
3
4
5
…
200
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Appendix C: ICD-10-PCS THA and TKA CODES
Code
0SRB
0SRB0
0SRB019

0SRB01A

0SRB01Z
0SRB029

0SRB02A

0SRB02Z

0SRB039

0SRB03A

0SRB03Z
0SRB049

0SRB04A

0SRB04Z

0SRB069

Procedure
Replacement of Left Hip Joint
Replacement of Left Hip Joint, Open
Approach
Replacement of Left Hip Joint with Metal
Synthetic Substitute, Cemented, Open
Approach
Replacement of Left Hip Joint with Metal
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Left Hip Joint with Metal
Synthetic Substitute, Open Approach
Replacement of Left Hip Joint with Metal on
Polyethylene Synthetic Substitute, Cemented,
Open Approach
Replacement of Left Hip Joint with Metal on
Polyethylene Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint with Metal on
Polyethylene Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint with Ceramic
Synthetic Substitute, Cemented, Open
Approach
Replacement of Left Hip Joint with Ceramic
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Left Hip Joint with Ceramic
Synthetic Substitute, Open Approach
Replacement of Left Hip Joint with Ceramic
on Polyethylene Synthetic Substitute,
Cemented, Open Approach
Replacement of Left Hip Joint with Ceramic
on Polyethylene Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint with Ceramic
on Polyethylene Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint with Oxidized
Zirconium on Polyethylene Synthetic
Substitute, Cemented, Open Approach
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0SRB06A

0SRB06Z

0SRB07Z

0SRB0J9
0SRB0JA
0SRB0JZ
0SRB0KZ

0SR9
0SR90
0SR9019

0SR901A

0SR901Z
0SR9029

0SR902A

0SR902Z

0SR9039

0SR903A

Replacement of Left Hip Joint with Oxidized
Zirconium on Polyethylene Synthetic
Substitute, Uncemented, Open Approach
Replacement of Left Hip Joint with Oxidized
Zirconium on Polyethylene Synthetic
Substitute, Open Approach
Replacement of Left Hip Joint with
Autologous Tissue Substitute, Open
Approach
Replacement of Left Hip Joint with Synthetic
Substitute, Cemented, Open Approach
Replacement of Left Hip Joint with Synthetic
Substitute, Uncemented, Open Approach
Replacement of Left Hip Joint with Synthetic
Substitute, Open Approach
Replacement of Left Hip Joint with
Nonautologous Tissue Substitute, Open
Approach
Replacement of Right Hip Joint
Replacement of Right Hip Joint, Open
Approach
Replacement of Right Hip Joint with Metal
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Hip Joint with Metal
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Right Hip Joint with Metal
Synthetic Substitute, Open Approach
Replacement of Right Hip Joint with Metal on
Polyethylene Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Hip Joint with Metal on
Polyethylene Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint with Metal on
Polyethylene Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint with Ceramic
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Hip Joint with Ceramic
Synthetic Substitute, Uncemented, Open
Approach
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0SR903Z
0SR9049

0SR904A

0SR904Z

0SR9069

0SR906A

0SR906Z

0SR907Z

0SR90J9

0SR90JA

0SR90JZ
0SR90KZ

0SRE
0SRE0
0SRE009

0SRE00A

Replacement of Right Hip Joint with Ceramic
Synthetic Substitute, Open Approach
Replacement of Right Hip Joint with Ceramic
on Polyethylene Synthetic Substitute,
Cemented, Open Approach
Replacement of Right Hip Joint with Ceramic
on Polyethylene Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint with Ceramic
on Polyethylene Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Hip Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Right Hip Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Open Approach
Replacement of Right Hip Joint with
Autologous Tissue Substitute, Open
Approach
Replacement of Right Hip Joint with
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Hip Joint with
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Right Hip Joint with
Synthetic Substitute, Open Approach
Replacement of Right Hip Joint with
Nonautologous Tissue Substitute, Open
Approach
Replacement of Left Hip Joint
Replacement of Left Hip Joint, Open
Approach
Replacement of Left Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Cemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Uncemented, Open Approach
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0SRE00Z

0SRE019

0SRE01A

0SRE01Z

0SRE039

0SRE03A

0SRE03Z

0SRE07Z

0SRE0J9

0SRE0JA

0SRE0JZ

0SRE0KZ

0SRA
0SRA0
0SRA009

0SRA00A

Replacement of Left Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Metal Synthetic Substitute,
Cemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Metal Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Metal Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Cemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint, Acetabular
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Right Hip Joint
Replacement of Right Hip Joint, Open
Approach
Replacement of Right Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Cemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Uncemented, Open Approach
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0SRA00Z

0SRA019

0SRA01A

0SRA01Z

0SRA039

0SRA03A

0SRA03Z

0SRA07Z

0SRA0J9

0SRA0JA

0SRA0JZ

0SRA0KZ

0SRS
0SRS0
0SRS019

0SRS01A

Replacement of Right Hip Joint, Acetabular
Surface with Polyethylene Synthetic
Substitute, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Metal Synthetic Substitute,
Cemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Metal Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Metal Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Cemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Ceramic Synthetic Substitute,
Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Left Hip Joint, Acetabular
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint, Acetabular
Surface with Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint, Acetabular
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Left Hip Joint, Femoral
Surface
Replacement of Left Hip Joint, Femoral
Surface, Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Metal Synthetic Substitute,
Cemented, Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Metal Synthetic Substitute,
Uncemented, Open Approach
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0SRS01Z

0SRS039

0SRS03A

0SRS03Z

0SRS07Z

0SRS0J9

0SRS0JA

0SRS0JZ

0SRS0KZ

0SRR
0SRR0
0SRR019

0SRR01A

0SRR01Z

0SRR039

0SRR03A

Replacement of Left Hip Joint, Femoral
Surface with Metal Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Cemented, Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Hip Joint, Femoral
Surface with Synthetic Substitute, Open
Approach
Replacement of Left Hip Joint, Femoral
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Right Hip Joint, Femoral
Surface
Replacement of Right Hip Joint, Femoral
Surface, Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Metal Synthetic Substitute,
Cemented, Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Metal Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Metal Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Cemented, Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Uncemented, Open Approach
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0SRR03Z

0SRR07Z

0SRR0J9

0SRR0JA

0SRR0JZ

0SRR0KZ

0SRD
0SRD0
0SRD069

0SRD06A

0SRD06Z

0SRD07Z

0SRD0J9

0SRD0JA

0SRD0JZ
0SRD0KZ

Replacement of Right Hip Joint, Femoral
Surface with Ceramic Synthetic Substitute,
Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Hip Joint, Femoral
Surface with Synthetic Substitute, Open
Approach
Replacement of Right Hip Joint, Femoral
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Left Knee Joint
Replacement of Left Knee Joint, Open
Approach
Replacement of Left Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Cemented, Open
Approach
Replacement of Left Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Left Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Open Approach
Replacement of Left Knee Joint with
Autologous Tissue Substitute, Open
Approach
Replacement of Left Knee Joint with
Synthetic Substitute, Cemented, Open
Approach
Replacement of Left Knee Joint with
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Left Knee Joint with
Synthetic Substitute, Open Approach
Replacement of Left Knee Joint with
Nonautologous Tissue Substitute, Open
Approach)
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0SRD0L9

Replacement of Left Knee Joint with
Unicondylar Synthetic Substitute, Cemented,
Open Approach

0SRD0LA

Replacement of Left Knee Joint with
Unicondylar Synthetic Substitute,
Uncemented, Open Approach

0SRD0LZ

Replacement of Left Knee Joint with
Unicondylar Synthetic Substitute, Open
Approach

0SRC
0SRC0

Replacement of Right Knee Joint
Replacement of Right Knee Joint, Open
Approach
Replacement of Right Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Right Knee Joint with
Oxidized Zirconium on Polyethylene
Synthetic Substitute, Open Approach
Replacement of Right Knee Joint with
Autologous Tissue Substitute, Open
Approach
Replacement of Right Knee Joint with
Synthetic Substitute, Cemented, Open
Approach
Replacement of Right Knee Joint with
Synthetic Substitute, Uncemented, Open
Approach
Replacement of Right Knee Joint with
Synthetic Substitute, Open Approach
Replacement of Right Knee Joint with
Nonautologous Tissue Substitute, Open
Approach)
Replacement of Right Knee Joint with
Unicondylar Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Knee Joint with
Unicondylar Synthetic Substitute,
Uncemented, Open Approach

0SRC069

0SRC06A

0SRC06Z

0SRC07Z

0SRC0J9

0SRC0JA

0SRC0JZ
0SRC0KZ

0SRC0L9

0SRC0LA
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0SRC0LZ

0SRU
0SRU0
0SRU07Z

Replacement of Right Knee Joint with
Unicondylar Synthetic Substitute, Open
Approach
Replacement of Left Knee Joint, Femoral
Surface
Replacement of Left Knee Joint, Femoral
Surface, Open Approach
Replacement of Left Knee Joint, Femoral
Surface with Autologous Tissue Substitute,
Open Approach

0SRU0J9

Replacement of Left Knee Joint, Femoral
Surface with Synthetic Substitute, Cemented,
Open Approach

0SRU0JA

Replacement of Left Knee Joint, Femoral
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Knee Joint, Femoral
Surface with Synthetic Substitute, Open
Approach
Replacement of Left Knee Joint, Femoral
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Right Knee Joint, Femoral
Surface
Replacement of Right Knee Joint, Femoral
Surface, Open Approach
Replacement of Right Knee Joint, Femoral
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Right Knee Joint, Femoral
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Knee Joint, Femoral
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Knee Joint, Femoral
Surface with Synthetic Substitute, Open
Approach
Replacement of Right Knee Joint, Femoral
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Left Knee Joint, Tibial
Surface

0SRU0JZ

0SRU0KZ

0SRT
0SRT0
0SRT07Z

0SRT0J9

0SRT0JA

0SRT0JZ

0SRT0KZ

0SRW
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0SRW0
0SRW07Z

0SRW0J9

0SRW0JA

0SRW0JZ

0SRW0KZ

0SRV
0SRV0
0SRV07Z

0SRV0J9

0SRV0JA

0SRV0JZ

0SRV0KZ

Replacement of Left Knee Joint, Tibial
Surface, Open Approach
Replacement of Left Knee Joint, Tibial
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Left Knee Joint, Tibial
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Left Knee Joint, Tibial
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Left Knee Joint, Tibial
Surface with Synthetic Substitute, Open
Approach
Replacement of Left Knee Joint, Tibial
Surface with Nonautologous Tissue
Substitute, Open Approach
Replacement of Right Knee Joint, Tibial
Surface
Replacement of Right Knee Joint, Tibial
Surface, Open Approach
Replacement of Right Knee Joint, Tibial
Surface with Autologous Tissue Substitute,
Open Approach
Replacement of Right Knee Joint, Tibial
Surface with Synthetic Substitute, Cemented,
Open Approach
Replacement of Right Knee Joint, Tibial
Surface with Synthetic Substitute,
Uncemented, Open Approach
Replacement of Right Knee Joint, Tibial
Surface with Synthetic Substitute, Open
Approach
Replacement of Right Knee Joint, Tibial
Surface with Nonautologous Tissue
Substitute, Open Approach
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